Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cannabix TechnologiesFRA:8CT +1.91%22 Cash Ratio is 4.92 as of Jan. 2026, which is 92% below its 10-year median of 58.17. GuruFocus rates FRA:8CT with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 841 Medical Devices & Instruments companies, Cannabix Technologies ranks better than 87.51% on this metric.
Cannabix Technologies has a Cash Ratio of 4.92. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Cannabix Technologies's Cash Ratio or its related term are showing as below:
FRA:8CT'
s Cash Ratio Range Over the Past 10 Years
Min: 4.92 Med: 58.17 Max: 524.8
Current: 4.92
During the past 13 years, Cannabix Technologies's highest Cash Ratio was 524.80. The lowest was 4.92. And the median was 58.17.
FRA:8CT's Cash Ratio is ranked better than 87.51% of 841
companies
in the Medical Devices & Instruments industry
Industry Median: 0.97
vs FRA:8CT: 4.92
Cannabix Technologies (FRA:8CT) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Cannabix Technologies's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cannabix Technologies Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cannabix Technologies's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Cannabix Technologies's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cannabix Technologies (FRA:8CT) has a Cash Ratio of 4.92 as of Jan. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Cannabix Technologies and its competitors. This is 92% below median its historical median of 58.17. Over the past decade, Cannabix Technologies' Cash Ratio has ranged from 4.92 to 524.80. According to the industry distribution chart, Cannabix Technologies ranks #105 out of 841 companies in the Medical Devices & Instruments industry, placing it in the top 12.5%.
Is Cannabix Technologies' Cash Ratio too high?
Cannabix Technologies' current Cash Ratio of 4.92 is 92% below median its 10-year median of 58.17. Over the past 10 years, this metric has ranged from a low of 4.92 to a high of 524.80. The Medical Devices & Instruments industry median Cash Ratio is 0.97. Cannabix Technologies' value of 4.92 is 407.2% above this industry median. Based on the distribution chart, Cannabix Technologies ranks #105 out of 841 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Cannabix Technologies has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Cannabix Technologies' Cash Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Cannabix Technologies ranks #105 out of 841 companies for Cash Ratio. This places Cannabix Technologies in the top 13% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.97. Cannabix Technologies' value of 4.92 is 407.2% above this benchmark. Historically, Cannabix Technologies' own Cash Ratio has ranged from 4.92 to 524.80 over the past decade. While the company's 10-year median is 58.17 vs. the industry median of 0.97, Cannabix Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.97, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cannabix Technologies's current Cash Ratio of 4.92 is 407.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Cannabix Technologies and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannabix Technologies's current Cash Ratio is 4.92, which is 92% below median its own 10-year median of 58.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannabix Technologies stock overvalued right now?
Cannabix Technologies (FRA:8CT) has a current Cash Ratio of 4.92. The current Cash Ratio is 4.92, which is 92% below median its 10-year median of 58.17 and 407.2% above the Medical Devices & Instruments industry median of 0.97. Cannabix Technologies' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Cannabix Technologies (FRA:8CT), the current Cash Ratio is 4.92 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cannabix Technologies Inc is engaged in the development of marijuana and alcohol breath testing technologies. Its products are Cannabix Marijuana Breath Test and BreathLogix Alcohol Breathalyzer.
22GF Score
Get the complete analysis for FRA:8CT
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8CT has been successfully added to your 
